In October 2014, the FDA approved* the expanded use of LYMPHOSEEK as a lymphatic mapping agent for solid tumors where it is a component of the intraoperative procedure. To support the approval, the FDA evaluated a combined analysis of three pivotal Phase 3 studies in melanoma, breast cancer, and oral cavity squamous cell carcinoma (SCC), which established the efficacy of LYMPHOSEEK in solid tumors.
Realize the benefits of LYMPHOSEEK, the first and only agent specifically designed for targeted lymphatic mapping* and guiding sentinel lymph node (SLN) biopsy. LYMPHOSEEK represents a new class of receptor-targeted lymphatic mapping agents—one that is purpose-built for lymphatic mapping in patients with solid tumors.1
Given its consistent pharmacodynamics properties, LYMPHOSEEK may facilitate benefits such as predictable scheduling of lymphatic mapping procedures and efficient resource utilization.